Ilse Van Hove
Overview
Explore the profile of Ilse Van Hove including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt M, Liebowitz M, Stein M, Grunfeld J, Van Hove I, Simmons W, et al.
Neuropsychopharmacology
. 2020 Oct;
46(5):1004-1010.
PMID: 33070154
JNJ-42165279 is a selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of fatty acid amides (FAA) including anandamide (AEA), palmitoylethanolamide (PEA), and N-oleoylethanolamide (OEA)....
2.
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, Van Der Ark P, et al.
Transl Psychiatry
. 2019 Oct;
9(1):240.
PMID: 31578318
In the original Article, Tables two and three had formatting issues which affected their clarity. This has been corrected in the PDF and HTML versions of this Article.
3.
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, Van Der Ark P, et al.
Transl Psychiatry
. 2019 Sep;
9(1):216.
PMID: 31481683
Excessive arousal has a role in the pathophysiology of major depressive disorder (MDD). Seltorexant (JNJ-42847922/MIN-202) is a selective antagonist of the human orexin-2 receptor (OX2R) that may normalize excessive arousal...
4.
Schwartz S, Etropolski M, Shapiro D, Rauschkolb C, Vinik A, Lange B, et al.
Clin Drug Investig
. 2014 Dec;
35(2):95-108.
PMID: 25503082
Background And Objective: Data from two similarly designed studies of tapentadol extended release (ER) for managing neuropathic pain associated with diabetic peripheral neuropathy (DPN; NCT00455520, NCT01041859) in adults were pooled...
5.
Imanaka K, Tominaga Y, Etropolski M, Van Hove I, Ohsaka M, Wanibe M, et al.
Curr Med Res Opin
. 2014 May;
30(9):1909-10.
PMID: 24818815
No abstract available.
6.
Imanaka K, Tominaga Y, Etropolski M, Van Hove I, Ohsaka M, Wanibe M, et al.
Curr Med Res Opin
. 2013 Aug;
29(10):1399-409.
PMID: 23937387
Objective: This phase 3 study evaluated the efficacy and safety of tapentadol extended release (ER) compared with oxycodone controlled release (CR) for the management of moderate to severe, chronic malignant...
7.
Afilalo M, Etropolski M, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al.
Clin Drug Investig
. 2010 Jul;
30(8):489-505.
PMID: 20586515
Background: Tapentadol is a novel, centrally acting analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibitor activity. Objective: to evaluate the efficacy and safety of Tapentadol extended release (ER) compared...
8.
Buynak R, Shapiro D, Okamoto A, Van Hove I, Rauschkolb C, Steup A, et al.
Expert Opin Pharmacother
. 2010 Jun;
11(11):1787-804.
PMID: 20578811
Objective: To evaluate the efficacy and safety of tapentadol extended release (ER) for the management of moderate to severe chronic low back pain. Research Design: Patients (N = 981) were...
9.
Haas M, DelBello M, Pandina G, Kushner S, Van Hove I, Augustyns I, et al.
Bipolar Disord
. 2009 Oct;
11(7):687-700.
PMID: 19839994
Objectives: To evaluate the efficacy, safety, and tolerability of risperidone monotherapy for the treatment of an acute mixed or manic episode in children and adolescents with bipolar I disorder. Methods:...
10.
Hartrick C, Van Hove I, Stegmann J, Oh C, Upmalis D
Clin Ther
. 2009 Mar;
31(2):260-71.
PMID: 19302899
Objectives: The primary objective of this study was to assess the efficacy and tolerability of tapentadol immediate release (IR) in patients who were candidates for joint replacement surgery due to...